Overall, a combination of a SUMOylation inhibitor and FXR agonist is a promising treatment for liver fibrosis, including NASH, indicating another potential treatment option for utilizing FXR against various types of liver fibrosis. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatohepatitis.